Aytu BioPharma, Inc. (AYTU)
USD 1.03
(0.98%)
USD 1.03
(0.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 59.84 Million USD | -23.29% |
| 2023 | 78.96 Million USD | -10.66% |
| 2022 | 88.38 Million USD | 31.06% |
| 2021 | 67.44 Million USD | 64.43% |
| 2020 | 41.01 Million USD | 86.73% |
| 2019 | 21.96 Million USD | 12.91% |
| 2018 | 19.45 Million USD | -5.86% |
| 2017 | 20.66 Million USD | 30.71% |
| 2016 | 15.8 Million USD | 102.53% |
| 2015 | 7.8 Million USD | 21.86% |
| 2014 | 6.4 Million USD | 11726.61% |
| 2013 | 54.16 Thousand USD | -6.78% |
| 2012 | 58.1 Thousand USD | -56.51% |
| 2011 | 133.61 Thousand USD | 135.49% |
| 2010 | 56.74 Thousand USD | -1.44% |
| 2009 | 57.57 Thousand USD | 4.71% |
| 2008 | 54.98 Thousand USD | 17.26% |
| 2007 | 46.89 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 12.61 Million USD | 0.57% |
| 2024 Q1 | 14.98 Million USD | -4.91% |
| 2024 Q4 | 13.43 Million USD | 23.36% |
| 2024 Q2 | 12.53 Million USD | -16.31% |
| 2023 Q4 | 15.75 Million USD | -28.5% |
| 2023 Q3 | 22.03 Million USD | 2.56% |
| 2023 FY | 78.96 Million USD | -10.66% |
| 2023 Q1 | 19.68 Million USD | -10.3% |
| 2023 Q2 | 21.48 Million USD | 9.15% |
| 2022 Q3 | 22.14 Million USD | -6.14% |
| 2022 Q4 | 21.94 Million USD | -0.9% |
| 2022 FY | 88.38 Million USD | 31.06% |
| 2022 Q2 | 23.59 Million USD | 13.96% |
| 2022 Q1 | 20.7 Million USD | -22.61% |
| 2021 Q1 | 13.25 Million USD | -20.74% |
| 2021 Q4 | 26.75 Million USD | 39.98% |
| 2021 Q2 | 14.72 Million USD | 11.06% |
| 2021 Q3 | 19.11 Million USD | 29.8% |
| 2021 FY | 67.44 Million USD | 64.43% |
| 2020 Q4 | 16.72 Million USD | 52.75% |
| 2020 FY | 41.01 Million USD | 86.73% |
| 2020 Q3 | 10.95 Million USD | 45.31% |
| 2020 Q1 | 5.79 Million USD | 2.7% |
| 2020 Q2 | 7.53 Million USD | 29.95% |
| 2019 Q2 | 5.82 Million USD | 31.16% |
| 2019 Q1 | 4.43 Million USD | -1.59% |
| 2019 Q4 | 5.64 Million USD | -6.82% |
| 2019 FY | 21.96 Million USD | 12.91% |
| 2019 Q3 | 6.06 Million USD | 4.11% |
| 2018 Q1 | 5.14 Million USD | 742.2% |
| 2018 FY | 19.45 Million USD | -5.86% |
| 2018 Q4 | 4.5 Million USD | -12.26% |
| 2018 Q3 | 5.13 Million USD | 10.31% |
| 2018 Q2 | 4.65 Million USD | -9.44% |
| 2017 Q3 | 5.42 Million USD | 22.23% |
| 2017 Q2 | 4.44 Million USD | -31.39% |
| 2017 Q4 | 610.87 Thousand USD | -88.75% |
| 2017 FY | 20.66 Million USD | 30.71% |
| 2017 Q1 | 6.47 Million USD | 1.1% |
| 2016 Q3 | 3.55 Million USD | 9.77% |
| 2016 Q4 | 6.4 Million USD | 80.08% |
| 2016 Q1 | 2.61 Million USD | 16.4% |
| 2016 Q2 | 3.23 Million USD | 23.95% |
| 2016 FY | 15.8 Million USD | 102.53% |
| 2015 Q1 | 10.79 Thousand USD | -11.05% |
| 2015 Q4 | 2.24 Million USD | 22.66% |
| 2015 Q3 | 1.83 Million USD | 11868.99% |
| 2015 Q2 | 15.29 Thousand USD | 41.7% |
| 2015 FY | 7.8 Million USD | 21.86% |
| 2014 Q1 | 9073.00 USD | -33.81% |
| 2014 Q2 | 15 Thousand USD | 65.4% |
| 2014 Q4 | 12.13 Thousand USD | -40.99% |
| 2014 Q3 | 20.55 Thousand USD | 37.0% |
| 2014 FY | 6.4 Million USD | 11726.61% |
| 2013 Q2 | 18.83 Thousand USD | -0.47% |
| 2013 FY | 54.16 Thousand USD | -6.78% |
| 2013 Q4 | 13.7 Thousand USD | 9.22% |
| 2013 Q3 | 12.55 Thousand USD | -33.36% |
| 2013 Q1 | 18.92 Thousand USD | 70.69% |
| 2012 FY | 58.1 Thousand USD | -56.51% |
| 2012 Q4 | 11.08 Thousand USD | 20.19% |
| 2012 Q3 | 9223.00 USD | -51.14% |
| 2012 Q2 | 18.87 Thousand USD | -73.31% |
| 2012 Q1 | 70.73 Thousand USD | 253.3% |
| 2011 Q3 | 26.31 Thousand USD | 58.98% |
| 2011 Q2 | 16.55 Thousand USD | 26.2% |
| 2011 Q4 | 20.02 Thousand USD | -23.91% |
| 2011 Q1 | 13.11 Thousand USD | -5.09% |
| 2011 FY | 133.61 Thousand USD | 135.49% |
| 2010 FY | 56.74 Thousand USD | -1.44% |
| 2010 Q1 | 10.41 Thousand USD | -0.98% |
| 2010 Q2 | 18.47 Thousand USD | 77.39% |
| 2010 Q3 | 11.33 Thousand USD | -38.66% |
| 2010 Q4 | 13.81 Thousand USD | 21.93% |
| 2009 Q4 | 10.51 Thousand USD | -30.48% |
| 2009 Q3 | 15.13 Thousand USD | -29.65% |
| 2009 Q2 | 21.5 Thousand USD | 82.26% |
| 2009 Q1 | 11.8 Thousand USD | -31.86% |
| 2009 FY | 57.57 Thousand USD | 4.71% |
| 2008 Q4 | 17.31 Thousand USD | 63.06% |
| 2008 Q3 | 10.62 Thousand USD | -30.32% |
| 2008 Q2 | 15.24 Thousand USD | 36.26% |
| 2008 Q1 | 11.18 Thousand USD | -18.58% |
| 2008 FY | 54.98 Thousand USD | 17.26% |
| 2007 Q4 | 13.74 Thousand USD | -8.14% |
| 2007 FY | 46.89 Thousand USD | 0.0% |
| 2007 Q3 | 14.95 Thousand USD | 113.46% |
| 2007 Q2 | 7007.00 USD | 0.0% |
| 2006 Q4 | 1905.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -625.081% |
| Alpha Teknova, Inc. | 45.85 Million USD | -30.487% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 69.467% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -33.411% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 62.414% |
| Cosmos Health Inc. | 26.18 Million USD | -128.565% |
| Journey Medical Corporation | 54.59 Million USD | -9.609% |
| Embecta Corp. | 528.4 Million USD | 88.675% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 77.992% |
| Dynavax Technologies Corporation | 219.14 Million USD | 72.694% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 89.858% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 81.665% |
| PainReform Ltd. | 9.58 Million USD | -524.374% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -355.942% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -355.942% |
| SCYNEXIS, Inc. | 51.84 Million USD | -15.414% |
| Safety Shot Inc | 12.1 Million USD | -394.15% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1849.701% |
| Procaps Group, S.A. | 199.47 Million USD | 70.002% |
| Theratechnologies Inc. | 72.75 Million USD | 17.752% |
| Harrow Health, Inc. | 89.97 Million USD | 33.491% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -533.496% |
| Biofrontera Inc. | 39.95 Million USD | -49.753% |
| DURECT Corporation | 43.71 Million USD | -36.887% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 88.688% |
| Cronos Group Inc. | 96.7 Million USD | 38.124% |
| OptiNose, Inc. | 85.1 Million USD | 29.684% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 74.221% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -52.836% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 725.876% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 80.951% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -514.952% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -39.032% |
| Radius Health, Inc. | 265.92 Million USD | 77.498% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -332.31% |
| ProPhase Labs, Inc. | 37.85 Million USD | -58.089% |
| Phibro Animal Health Corporation | 260.29 Million USD | 77.011% |
| Procaps Group S.A. | 187.24 Million USD | 68.042% |
| Alvotech | 285.43 Million USD | 79.036% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -509.059% |
| Viatris Inc. | 5.96 Billion USD | 98.997% |
| Rockwell Medical, Inc. | 15.37 Million USD | -289.229% |
| SIGA Technologies, Inc. | 22.04 Million USD | -171.469% |
| Tilray Brands, Inc. | 251.35 Million USD | 76.193% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -22.028% |
| Shineco, Inc. | 17.94 Million USD | -233.407% |
| PetIQ, Inc. | 192.72 Million USD | 68.951% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -1399.322% |
| Incannex Healthcare Limited | 30.05 Million USD | -99.115% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 96.252% |
| Alimera Sciences, Inc. | 62.64 Million USD | 4.472% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -7747.951% |
| Assertio Holdings, Inc. | 368.58 Million USD | 83.765% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -916.724% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -236.019% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -182.678% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -184.382% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 63.726% |
| Hempacco Co., Inc. | 7.59 Million USD | -687.736% |
| Talphera, Inc. | 11.99 Million USD | -398.916% |
| Alvotech | 285.43 Million USD | 79.036% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 57.474% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 82.65% |
| Currenc Group, Inc. | 24 Million USD | -149.312% |
| Kamada Ltd. | 45.42 Million USD | -31.731% |
| Indivior PLC | 911 Million USD | 93.431% |
| Evoke Pharma, Inc. | 12.4 Million USD | -382.206% |
| Flora Growth Corp. | 10.57 Million USD | -465.649% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -184.382% |
| Evolus, Inc. | 189.75 Million USD | 68.465% |
| HUTCHMED (China) Limited | 436.23 Million USD | 86.282% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 61.177% |
| Akanda Corp. | 3.48 Million USD | -1617.809% |